Skip to main content
. 2018 Jan 30;39(4):413–422. doi: 10.1093/asj/sjy019

Figure 3.

Figure 3.

Representative photographs of a 47-year-old female subject's lips and perioral area at (A) baseline, (B) 3 months, and (C) 1 year after treatment, and at 1 month after repeat treatment (D) with VYC-15L. She received initial treatment with 0.6 and 0.4 mL in the upper and lower lips, respectively, and touch-up treatment with 0.4 and 0.2 mL in the upper and lower lips, respectively. At repeat treatment, she received 0.95 and 0.65 mL in the upper and lower lips, respectively, 1 mL in the oral commissures, and 0.3 mL in the philtral columns. (A) LFS at Baseline = Moderate; (B) LFS at Month 3 = Marked; (C) LFS at Month 12 = Moderate; (D) LFS at Month 1R = Marked. LFS, Allergan Lip Fullness Scale; Month 1R, Month 1 after repeat treatment; VYC-15L, Juvéderm Volbella XC.